<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>2024 (2) TMI 1518 - ITAT HYDERABAD</title>
    <link>https://www.taxtmi.com/caselaws?id=460796</link>
    <description>The ITAT Hyderabad ruled on transfer pricing adjustments for raw material transfers between Non-SEZ and SEZ units. Both the assessee&#039;s methodology excluding 70% of products and the TPO&#039;s cherry-picking approach from 11 product families were rejected as inappropriate. The matter was remanded to TPO/AO to determine arm&#039;s length price using TNNM method with external/international comparables, allowing 3% tolerance range. The tribunal allowed weighted deduction under section 35(2AB) for entire R&amp;amp;D expenditure including clinical trials, following consistency with previous year&#039;s order. Additional depreciation claim was allowed as the AO failed to implement DRP directions without justification. Appeal was partly allowed.</description>
    <language>en-us</language>
    <pubDate>Mon, 19 Feb 2024 00:00:00 +0530</pubDate>
    <lastBuildDate>Thu, 20 Feb 2025 18:59:41 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=800102" rel="self" type="application/rss+xml"/>
    <item>
      <title>2024 (2) TMI 1518 - ITAT HYDERABAD</title>
      <link>https://www.taxtmi.com/caselaws?id=460796</link>
      <description>The ITAT Hyderabad ruled on transfer pricing adjustments for raw material transfers between Non-SEZ and SEZ units. Both the assessee&#039;s methodology excluding 70% of products and the TPO&#039;s cherry-picking approach from 11 product families were rejected as inappropriate. The matter was remanded to TPO/AO to determine arm&#039;s length price using TNNM method with external/international comparables, allowing 3% tolerance range. The tribunal allowed weighted deduction under section 35(2AB) for entire R&amp;amp;D expenditure including clinical trials, following consistency with previous year&#039;s order. Additional depreciation claim was allowed as the AO failed to implement DRP directions without justification. Appeal was partly allowed.</description>
      <category>Case-Laws</category>
      <law>Income Tax</law>
      <pubDate>Mon, 19 Feb 2024 00:00:00 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/caselaws?id=460796</guid>
    </item>
  </channel>
</rss>